Abstract
In primary and secondary prevention trials, statins have significantly lowered risk for adverse cardiovascular events and death — but some risk always remains. After LDL cholesterol levels have been reduced substantially by statin therapy, how much of the remaining vascular risk can be explained by continuing low levels …
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have